CRATETIN™

1. Asset overview

CRATETIN™ is an engineered creatine-based candidate program designed as a multiparticulate supplement platform to support maximal strength, high-intensity power and repeated-effort capacity in trained adults, with emphasis on performance superiority versus standard creatine monohydrate at equimolar creatine dose and improved GI tolerability and adherence.

The asset is presented as a technical development dossier (supplement – CMC + QbD + clinical blueprint), providing an integrated view from biological rationale and composition architecture to multiparticulate engineering, analytical strategy, stability, risk register, clinical program outline and regulatory positioning as a sports nutrition supplement.

Table 1 – Asset overview

2. Scientific rationale and functional target

CRATETIN™ is centered on preserving creatine’s phosphagenic mechanism while reshaping GI exposure and adherence through osmolytes, electrolytes and multiparticulate engineering.

Creatine backbone and performance

• Creatine increases muscle total creatine and phosphocreatine, enhancing rapid ATP resynthesis and supporting gains in 1RM, high-intensity power and training volume over 8–12 weeks of resistance training.
• The platform targets equivalence or superiority versus creatine monohydrate at equimolar creatine dose in at least one primary endpoint such as Δ1RM or repeated-effort capacity.
• Scientific foundations rely on decades of human data and position stands confirming creatine as a core ergogenic in sports nutrition.

Osmolytes and electrolytes for osmotic and recovery support

• Taurine is incorporated as a compatible osmolyte with roles in Ca²⁺ handling and cytoprotection under high-frequency contractions, with literature signals for modest performance and recovery benefits at sports doses.
• Betaine (trimethylglycine) contributes osmotic balance and methyl-donor function, with meta-analytic signals for strength enhancement, particularly in lower-body performance.
• Sodium, potassium and magnesium support membrane excitability, Mg-ATP enzymology and sweat-related electrolyte balance, complementing osmolyte-rich solute loads.

Multiparticulate engineering and GI tolerability

• Pellets or granules disperse along the GI tract, reducing local concentration spikes and luminal hyperosmolarity seen with grams of solute in small fluid volumes.
• This architecture is designed to flatten luminal exposure, reduce GI complaints (bloating, cramps, diarrhea) and improve real-world comfort.
• Improved tolerability is expected to translate into better adherence, higher cumulative training stimulus and superior performance outcomes over time.

Complementarity to conventional creatine monohydrate supplements

• CRATETIN™ is positioned as an engineered alternative to standard creatine monohydrate supplements, focusing on GI exposure, osmolar profile and adherence rather than changing the underlying creatine mechanism.
• It is intended to be used under sports nutrition guidance, in trained adults combining supplementation with structured resistance or mixed training.
• The design enables integration into existing regimens while providing a differentiated performance and user-experience narrative.

3. Technological concept

Core physicochemical and dosage-form features

• Multiparticulate units (pellets or granules) containing creatine, taurine, betaine and electrolytes, engineered for rapid yet controlled dissolution.
• Intended presentation as hard capsules filled with pellets and/or flavored sachet powders to be dispersed in water at specified volumes.
• Compositional windows and osmolarity specifications defined for the reconstituted solution at label dose and volume.
• Stability-focused design with attention to creatine → creatinine conversion, moisture control and protection against heat and humidity.

Use pattern and user profile

• Daily use in adults engaged in resistance or high-intensity training, typically at 3–5 g/day creatine-equivalent without mandatory loading phase.
• Label guidance for reconstitution volume, timing relative to training and “mix and consume” instructions to minimize in-solution degradation.
• Positioned for medium- to long-term use alongside structured training plans and adequate diet, consistent with supplement practice.

API and finished product engineering (high level)

• Creatine (monohydrate or permitted creatine forms) as the central active, combined with taurine, betaine and a defined electrolyte profile (Na⁺/K⁺/Mg²⁺).
• Matrix and coating materials such as maltodextrin carriers, PVP/HPMC binders and optional HPMC/PVA films to tune dissolution and protect from moisture.
• Granulation or extrusion–spheronization for core formation, followed by layering and optional film-coating under Quality by Design (QbD) principles.
• Analytical and process controls linking CPPs (e.g., inlet temperature, coating gain, bed moisture) to CQAs (assay, dissolution, osmolarity, creatinine limits, particle size distribution).

4. Potential positioning axes for the product

Based on the mechanistic and translational synthesis, CRATETIN™ supports multiple positioning axes for a single supplement product or a small line, depending on commercial and regulatory strategy.

Table 2 – Example positioning axes

5. Differentiators versus conventional creatine monohydrate supplements

Mechanistic clarity with added functional modules
Creatine’s phosphagenic mechanism is preserved while osmolyte and electrolyte modules provide coherent support for osmotic balance, excitability and recovery within a single multiparticulate platform.

Engineered tolerability and osmolar profile
Multiparticulate engineering and defined osmolarity specifications for reconstituted solutions are used to reduce local luminal hyperosmolarity, targeting lower rates of GI discomfort and improved day-to-day comfort.

High functional density with adherence focus
The composition architecture and dosage-form choices are oriented to deliver creatine and co-actives efficiently while supporting adherence through improved user experience and practical dosing.

Programmatic and IP framing
The asset is framed as a full technical program — composition windows, CPP→CQA maps, specifications and clinical blueprint — enabling partners to build defensible, differentiated supplement products instead of simple commodity creatine SKUs.

6. Structure of the technical program

The CRATETIN™ dossier is organized as a structured supplement program that can serve as the technical backbone for development and commercialization.

Table 3 – Main components of the CRATETIN™ technical program

7. Intended regulatory classification

For commercial use, CRATETIN™ is intended to support the development of:

• Creatine-based dietary / food supplements for adults, using only ingredients with established supplement precedent.
• Formulations that respect local positive lists, maximum levels, labelling standards and sports nutrition good practice.
• Claim sets expressed in structure–function language, anchored in strength, performance and recovery support rather than disease treatment.

Examples of conservative claim directions (to be adapted to local regulations) include:

• Helps support maximal strength and high-intensity performance when used with structured training and adequate diet.
• Designed to support training volume, repeated-effort capacity and workout recovery in active adults.
• Engineered supplement architecture aimed at improving comfort and adherence compared with conventional creatine monohydrate products.

8. Professional statement on use and development

CRATETIN™ is presented as a development asset intended for qualified technical and commercial teams in:

• R&D and formulation for sports nutrition supplements,
• Quality and CMC,
• Clinical and performance research,
• Regulatory and scientific affairs in the supplement / sports nutrition space,
• Business development and brand owners seeking differentiated creatine-based products.

Moving from concept to marketed supplement involves, under the responsibility of the licensee’s technical team:

• Defining final dosage form, flavor system and sensory profile suitable for the target market and channels.
• Conducting compatibility, performance and stability studies on the selected formulation and packaging.
• Qualifying analytical methods and setting specifications consistent with the chosen supplement category and jurisdictions.
• Planning labeling and regulatory submissions or notifications in line with regional supplement regulations.
• When relevant, executing human studies focused on strength, performance, tolerability and adherence to support commercial positioning.

The asset is not intended for direct use by end consumers and does not, by itself, constitute a finished supplement product. It provides a scientific, technological and commercial framework to accelerate the design, evaluation and launch of a creatine-based supplement product based on CRATETIN™, while maintaining alignment with regulatory boundaries for dietary and sports nutrition supplements.